Post-earnings recap
Reported
Tue, Nov 6, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Xenon Pharmaceutical's earnings report showed a loss per share of $0.63, which contributed to a 4.5% decline in stock price. The lack of revenue information and forward guidance may have raised concerns among investors. The management's focus on clinical trials suggests they are prioritizing long-term growth over immediate financial performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.63 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach, emphasizing the importance of their clinical trials. They did not provide any updates on future guidance.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing clinical trials and product development.